Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 137

1.

Genomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine.

Chen X, Zhang L, Ren S, Li X, Zhou F, Li W, Gao G, He Y, Zhou C.

Med Oncol. 2014 Apr;31(4):865. doi: 10.1007/s12032-014-0865-z. Epub 2014 Feb 18.

PMID:
24535606
[PubMed - indexed for MEDLINE]
2.

Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.

Liu L, Yuan P, Wu C, Zhang X, Wang F, Guo H, Zhong R, Xu Y, Wu J, Yu D, Wu T, Zhang X, Nie S, Miao X, Lin D.

Lung Cancer. 2011 Jul;73(1):110-5. doi: 10.1016/j.lungcan.2010.11.004. Epub 2010 Dec 3.

PMID:
21129812
[PubMed - indexed for MEDLINE]
3.

Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.

Liao WY, Shih JY, Chang GC, Cheng YK, Yang JC, Chen YM, Yu CJ.

J Thorac Oncol. 2012 Jun;7(6):973-81. doi: 10.1097/JTO.0b013e31824fe98c.

PMID:
22551904
[PubMed - indexed for MEDLINE]
4.

Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.

Xiong L, Cheng J, Gao J, Wang J, Liu X, Wang L.

Clin Lung Cancer. 2013 Jul;14(4):433-9. doi: 10.1016/j.cllc.2013.01.004. Epub 2013 Mar 22.

PMID:
23522953
[PubMed - indexed for MEDLINE]
5.

Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.

Kim SH, Lee GW, Lee MJ, Cho YJ, Jeong YY, Kim HC, Lee JD, Hwang YS, Kim IS, Lee S, Oh SY.

Lung Cancer. 2012 Sep;77(3):578-84. doi: 10.1016/j.lungcan.2012.04.016. Epub 2012 May 18.

PMID:
22608006
[PubMed - indexed for MEDLINE]
6.

Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.

Xu JL, Wang ZW, Hu LM, Yin ZQ, Huang MD, Hu ZB, Shen HB, Shu YQ.

Asian Pac J Cancer Prev. 2012;13(5):2157-62.

PMID:
22901187
[PubMed - indexed for MEDLINE]
Free Article
7.

Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy.

Ren S, Zhou S, Wu F, Zhang L, Li X, Zhang J, Xu J, Lv M, Zhang J, Zhou C.

Lung Cancer. 2012 Jan;75(1):102-9. doi: 10.1016/j.lungcan.2011.05.023. Epub 2011 Jun 14.

PMID:
21676483
[PubMed - indexed for MEDLINE]
8.

Predictive effect of XPA and XPD polymorphisms on survival of advanced NSCLC patients treated with platinum-based chemotherapy: a three-dimensional (3-D), polyacrylamide gel-based DNA microarray method.

Cheng H, Qin Q, Sun X, Li F, Sun N, Cheng L, Lu Z, Chen B.

Technol Cancer Res Treat. 2013 Oct;12(5):473-82. doi: 10.7785/tcrt.2012.500337. Epub 2013 Apr 24.

PMID:
23617284
[PubMed - indexed for MEDLINE]
9.

Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study.

Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, Bard MP, Doodeman VD, Smits PH, Vincent A, Huitema AD, Beijnen JH, Schellens JH.

Cancer. 2012 May 1;118(9):2466-75. doi: 10.1002/cncr.26562. Epub 2011 Sep 28.

PMID:
22031394
[PubMed - indexed for MEDLINE]
Free Article
10.

The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC.

Wang YD, Ha MW, Cheng J, Zhang WL, Cong X, Tong CY, Sun J.

Oncol Rep. 2012 Apr;27(4):979-86. doi: 10.3892/or.2011.1591. Epub 2011 Dec 13.

PMID:
22179630
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trial.

Greco FA, Gray JR Jr, Thompson DS, Burris HA 3rd, Erland JB, Barton JH Jr, Litchy S, Houston GA, Butts JA, Webb C, Scott C, Hainsworth JD.

Cancer. 2002 Sep 15;95(6):1279-85.

PMID:
12216096
[PubMed - indexed for MEDLINE]
Free Article
12.

Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network.

Greco FA, Spigel DR, Kuzur ME, Shipley D, Gray JR, Thompson DS, Burris HA, Yardley DA, Pati A, Webb CD, Gandhi JG, Hainsworth JD.

Clin Lung Cancer. 2007 Sep;8(8):483-7.

PMID:
17922972
[PubMed - indexed for MEDLINE]
13.

Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.

Kubota K, Kawahara M, Ogawara M, Nishiwaki Y, Komuta K, Minato K, Fujita Y, Teramukai S, Fukushima M, Furuse K; Japan Multi-National Trial Organisation.

Lancet Oncol. 2008 Dec;9(12):1135-42. doi: 10.1016/S1470-2045(08)70261-4. Epub 2008 Nov 13.

PMID:
19013107
[PubMed - indexed for MEDLINE]
14.

Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer.

Luo J, Leaw SJ, Xu Y, Zheng D.

Med Oncol. 2011 Dec;28(4):1418-24. doi: 10.1007/s12032-010-9575-3. Epub 2010 Jul 27.

PMID:
20661668
[PubMed - indexed for MEDLINE]
15.

Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival.

Liu L, Wu C, Wang Y, Zhong R, Duan S, Wei S, Lin S, Zhang X, Tan W, Yu D, Nie S, Miao X, Lin D.

J Thorac Oncol. 2011 Nov;6(11):1793-800. doi: 10.1097/JTO.0b013e3182272273.

PMID:
21841506
[PubMed - indexed for MEDLINE]
16.

Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.

Tiseo M, Giovannetti E, Tibaldi C, Camerini A, Di Costanzo F, Barbieri F, Burgers JA, Vincent A, Peters GJ, Smit EF, Ardizzoni A.

Lung Cancer. 2012 Oct;78(1):92-9. doi: 10.1016/j.lungcan.2012.07.009. Epub 2012 Aug 11.

PMID:
22889494
[PubMed - indexed for MEDLINE]
17.

Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs.

Li XD, Han JC, Zhang YJ, Li HB, Wu XY.

Asian Pac J Cancer Prev. 2013;14(1):145-8.

PMID:
23534713
[PubMed - indexed for MEDLINE]
Free Article
18.

RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.

Dong S, Guo AL, Chen ZH, Wang Z, Zhang XC, Huang Y, Xie Z, Yan HH, Cheng H, Wu YL.

J Hematol Oncol. 2010 Mar 13;3:10. doi: 10.1186/1756-8722-3-10.

PMID:
20226083
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

XPG is predictive gene of clinical outcome in advanced non-small-cell lung cancer with platinum drug therapy.

Zhang T, Sun J, Lv M, Zhang L, Wang X, Ren JC, Wang B.

Asian Pac J Cancer Prev. 2013;14(2):701-5.

PMID:
23621222
[PubMed - indexed for MEDLINE]
Free Article
20.

Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.

Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S, Di Marsico R, Antonuzzo A, Orlandini C, Ricciardi S, Del Tacca M, Peters GJ, Falcone A, Danesi R.

Clin Cancer Res. 2008 Mar 15;14(6):1797-803. doi: 10.1158/1078-0432.CCR-07-1364.

PMID:
18347182
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk